

Special Issue

Next Generation Sequencing: A Promising Tool for Vaccines and Other Biological Products

Message from the Guest Editors

Next-generation sequencing (NGS) has been proved to be a powerful high-throughput tool for strengthening our surveillance system through the genetic detection and characterization of infectious agents, as well as the identification of outbreaks and spill-over events. NGS aided the development of vaccines based on mRNA and DNA, the development of antiviral drugs and even the detection of minor variants based on either the partial- or whole-genome sequencing of any viral agent. It has shown great potential for adventitious agent testing through the successful identification of known and novel viruses, transforming the quality assessment of vaccines and other biological products. We are pleased to invite authors to contribute to this Special Issue focused on topics relevant to the theme “Next-Generation Sequencing: a promising tool for vaccines and other biological products”. This Special Issue aims to gather a comprehensive collection of articles that report key developments and emerging concepts in the area of next-generation sequencing related to the understanding of viral infections and vaccines.

Guest Editors

Dr. Srinivas Nellimarla

Department of Molecular and Cellular Biology, University of Guelph, 50 Stone Rd E, Guelph, ON N1G 2W1, Canada

Dr. Prasad Kesanakurti

College of Biological Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada

Deadline for manuscript submissions

closed (10 November 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/152988

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).